Uterine Fibroids – Epidemiology – Epidemiology – Uterine Fibroids – Mature Markets

Clarivate Epidemiology’s coverage of uterine fibroids comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of uterine fibroids for each country, as well as annualized case counts projected to the national population.

Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.

Clarivate Epidemiology’s uterine fibroids forecast will answer the following questions:

• How will changes in the levels of exposure to known risk or protective factors affect the number of people living with uterine fibroids?
• Of all people with uterine fibroids, how many in each country in the major mature pharmaceutical markets have been formally diagnosed?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of uterine fibroids over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts seven uterine fibroids patient populations, as follows:

• Total prevalent cases
• Diagnosed lifetime prevalent cases
• Diagnosed incidence cases
• Diagnosed lifetime prevalent cases with a history of hysterectomy
• Diagnosed lifetime prevalent cases without a history of hysterectomy
• Diagnosed drug treated prevalent cases
• Diagnosed non-drug treated prevalent cases